Topic

Blue Cross Blue Shield (BCBS Association)

A collection of 1330 issues

How to Get Ultomiris (Ravulizumab) Covered by Blue Cross Blue Shield in Michigan: Prior Authorization Forms, Timelines, and Appeals Guide

Answer Box: Quick Path to Ultomiris Approval in Michigan Blue Cross Blue Shield of Michigan requires prior authorization for Ultomiris (ravulizumab) under the medical benefit, with new step therapy requirements as of 2024. For commercial members, you must try an alternative therapy first; Medicare Advantage members need rituximab biosimilar trial
6 min read

How to Get Therakos CELLEX Photopheresis Covered by Blue Cross Blue Shield in New York: Complete Prior Authorization and Appeals Guide

Answer Box: Your Fast Track to Coverage Therakos CELLEX photopheresis is covered by Blue Cross Blue Shield plans in New York for CTCL and steroid-refractory GVHD when medical necessity criteria are met. The fastest path: have your hematologist/oncologist or dermatologist submit prior authorization with complete staging documentation, steroid-refractory evidence
5 min read

Work With Your Doctor to Get Defitelio (defibrotide) Approved by Blue Cross Blue Shield in Washington: Complete Prior Authorization Guide

Quick Answer: Defitelio (defibrotide) requires prior authorization from Blue Cross Blue Shield plans in Washington for hepatic VOD/SOS with organ dysfunction after HSCT. Success depends on partnering with your transplant team to document HSCT details, organ dysfunction, and meeting diagnostic criteria. Start by requesting your plan's Defitelio
6 min read

Work With Your Doctor to Get Xospata (Gilteritinib) Covered by Blue Cross Blue Shield in Pennsylvania: Forms, Appeals, and Success Scripts

Answer Box: Getting Xospata Covered by Blue Cross Blue Shield in Pennsylvania Blue Cross Blue Shield plans in Pennsylvania require prior authorization for Xospata (gilteritinib), which is approved for adults with relapsed/refractory FLT3-mutated AML. Success requires: (1) documented FLT3 mutation test results, (2) evidence of prior therapy failure, and
6 min read

How to Get Qinlock (ripretinib) Covered by Blue Cross Blue Shield in Washington: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Qinlock Covered in Washington Blue Cross Blue Shield requires prior authorization for Qinlock (ripretinib) for fourth-line GIST treatment in Washington. To get approved: (1) Confirm your specific Blue plan (Premera, Regence BlueShield, or other), (2) Submit complete prior authorization through your oncologist with documented failure of three
5 min read

Work With Your Doctor to Get Hetlioz (tasimelteon) Approved by Blue Cross Blue Shield in North Carolina: Complete Guide

Answer Box: Getting Hetlioz Covered in North Carolina Eligibility: Blue Cross Blue Shield North Carolina covers Hetlioz (tasimelteon) for FDA-approved conditions (Non-24-Hour Sleep-Wake Disorder in adults, Smith-Magenis syndrome sleep disturbances) with prior authorization. Fastest path: Work with a sleep specialist to document diagnosis, failed melatonin/ramelteon trials, and functional impact.
6 min read

How to Get Increlex (Mecasermin) Covered by Blue Cross Blue Shield in Georgia: Coding, Appeals & Prior Authorization Guide

Quick Answer: Getting Increlex Covered in Georgia Eligibility: Children with severe primary IGF-1 deficiency meeting strict diagnostic criteria. Fastest path: Submit prior authorization with complete diagnostic documentation (height ≤-3 SD, IGF-1 ≤-3 SD, normal GH levels). First step today: Contact your Blue Cross Blue Shield plan to confirm current PA
5 min read

How to Get Xospata (gilteritinib) Covered by Blue Cross Blue Shield in Florida: Prior Authorization, Appeals, and Success Strategies

Quick Answer: Blue Cross Blue Shield in Florida covers Xospata (gilteritinib) for relapsed/refractory FLT3-mutated AML with prior authorization. You'll need documented FLT3 mutation testing, prior therapy history, and a hematologist-oncologist prescription. Start by checking your plan's medication guide for PA requirements, then submit through your
6 min read